Detail akcie DNAPrint Genomic online

Business Summary: DNAPrint genomics, Inc. is a development-stage pharmaceutical company. As of March 15, 2007, the Company’s pharmacogenomics products were still in development. The Company generates revenues in its consumer, forensic and genotyping services, but these services have not resulted in the generation of significant revenues. During the year ended December 31, 2006, the Company’s revenues were from the sales of its ancestry product, AncestryByDNA and genotyping services. The Company provides services that range from sequencing and genotyping to the entire process of single nucleotide polymorphisms (SNP) discovery to large industrial customers. Contract genotyping is the process of reading a genetic sequence and identifying differences in the sequence letters. This information helps researchers understand how human differences are expressed at the gene level.
Financial Summary: BRIEF: For the nine months ended 30 September 2007, DNAPrint Genomics Inc revenues decreased 26% to $1.4M. Net loss decreased 92% to $690K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Gain on sale of investments available increase from $0K to $4.4M (income), Research & Development decrease of 37% to $3.3M (expense), Intr. Value of Conv. Debt & Detach.